Natixis Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.76M Buy
33,824
+8,365
+33% +$1.19M 0.01% 981
2026
Q2
$3.12M Buy
25,459
+2,821
+12% +$295K ﹤0.01% 1073
2026
Q1
$2.39M Buy
22,638
+2,143
+10% +$190K ﹤0.01% 1046
2025
Q4
$1.79M Buy
20,495
+3,640
+22% +$298K ﹤0.01% 1081
2025
Q3
$1.12M Buy
16,855
+3,413
+25% +$194K ﹤0.01% 1285
2025
Q2
$743K Buy
+13,442
New +$645K ﹤0.01% 1383

Other funds holding PTGX

Natixis Advisors's PTGX Position: Q3 2026 in Review

Natixis Advisors increased its Protagonist Therapeutics (PTGX) stake by 33% in Q3 2026, buying an estimated $1.19M and bringing the position to 33,824 shares worth $4.76M. The position accounts for 0.01% of the portfolio, ranked #981.

Natixis Advisors first reported a position in PTGX in Q2 2025 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Natixis Advisors held 33,824 shares of Protagonist Therapeutics worth $4.76M as of Q3 2026.
  • Natixis Advisors bought 8,365 Protagonist Therapeutics shares in Q3 2026, an estimated $1.19M.
  • Protagonist Therapeutics made up 0.01% of Natixis Advisors's portfolio in Q3 2026, its #981 holding.
  • Natixis Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Natixis Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.